Trial Profile
A retrospective, multicenter study to evaluate the efficacy and safety of 177Lu-PSMA-617 in patients with metastatic castration resistant prostate cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2017
Price :
$35
*
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 19 May 2017 New trial record